Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN

Journal of Leukocyte Biology

Volumn 72, Issue 1, 2002, Pages 83-92

  Jahrsdorfer B ^a   Jox, R ^a   Muhlenhoff L ^a   Tschoep, K ^a   Krug, A ^a   Rothenfusser, S ^a   Meinhardt, G ^a   Emmerich, B ^a   Endres, S ^a   Hartmann, G ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cationic lipids; High serum thymidine kinase; Lymphoma; Oligodeoxynucleotide

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; DINUCLEOTIDE; NOV 2009; OBLIMERSEN; OLIGODEOXYNUCLEOTIDE 2006; PROTEIN BCL 2; THYMIDINE KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER CELL CULTURE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE ACTIVITY; GENE CONTROL; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; APOPTOSIS; BCL-X PROTEIN; GENE EXPRESSION REGULATION; HUMANS; LEUKEMIA, B-CELL, CHRONIC; LYMPHOCYTE ACTIVATION; OLIGODEOXYRIBONUCLEOTIDES; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PHOSPHATIDYLETHANOLAMINES; PROTO-ONCOGENE PROTEINS C-BCL-2; THYMIDINE KINASE; TUMOR CELLS, CULTURED;

EID: 18644380027     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Adams, J. M., Cory, S. (1998) The bcl-2 protein family: arbiters of cell survival. Science 281, 1322-1326.
2. Reed, J. C. (1995) Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr. Opin. Oncol. 7, 541-546.
3. Katsumata, M., Siegel, R. M., Louie, D. C., Miyashita, T., Tsujimoto, Y., Nowell, P. C., Greene, M. I., Reed, J. C. (1992) Differential effects of bcl-2 on T and B cells in transgenic mice. Proc. Natl. Acad. Sci. USA 89, 11376-11380.
4. Smith, K. G., Light, A., O'Reilly, L. A., Ang, S. M., Strasser, A., Tarlinton, D. (2000) bcl-2 transgene expression inhibits apoptosis in the germinal center and reveals differences in the selection of memory. B cells and bone marrow antibody-forming cells. J. Exp. Med. 191, 475-484.
5. Reed, J. C. (1995) bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol. Oncol. Clin. North Am. 9, 451-473.
6. Reed, J. C., Kitada, S., Takayama, S., Miyashita, T. (1994) Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann. Oncol. 1, 61-65.
7. Kitada, S., Andersen, J., Akar, S., Zapata, J. M., Takayama, S., Krajewski, S., Wang, H. G., Zhang, X., Bullrich, F., Croce, C. M., Rai, K., Hines, J., Reed, J. C. (1998) Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia; correlations with in vitro and in vivo chemoresponses. Blood 91, 3379-3389.
8. Kallander, C. F., Simonsson, B., Gronowitz, J. S., Nilsson, K. (1987) Serum deoxythymidine kinase correlates with peripheral lymphocyte thymidine uptake in chronic lymphocytic leukemia. Eur. J. Haematol. 38, 331-337.
9. Martinsson, U., Glimelius, B., Hagberg, H., Sundstrom, C. (1989) Primarily asymptomatic low-grade non-Hodgkin lymphomas: prediction of symptom-free survival and total survival. Eur. J. Haematol. 43, 332-338.
10. Kallander, C. F., Simonsson, B., Hagberg, H., Gronowitz, J. S. (1984) Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia. Cancer 54, 2450-2455.
11. Hallek, M., Wanders, L., Ostwald, M., Busch, R., Senekowitsch, R., Stem, S., Schick, H. D., Kuhn-Hallek, I., Emmerich, B. (1996) Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk. Lymphoma 22, 439-447.
12. Hallek, M., Langenmayer, I., Nerl, C., Knauf, W., Dietzfelbinger, H., Adorf, D., Ostwald, M., Busch, R., Kuhn-Hallek, I., Thiel, E., Enimerich, B. (1999) Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 93, 1732-1737.
13. Stein, C. A. (2000) Is irrelevant cleavage the price of antisense efficacy? Pharmacol. Ther. 85, 231-236.
14. Cotter, F. E. (1999) Antisense therapy of hematologic malignancies. Semin. Hematol. 36, 9-14.
15. Gewirtz, A. M. (2000) Oligonucleotide therapeutics: a step forward. J. Clin. Oncol. 18, 1809-1811.
16. Ho, P. T., Parkinson, D. R. (1997) Antisense oligonucleotides as therapeutics for malignant diseases. Semin. Oncol. 24, 187-202.
17. Reed, J. C., Stein, C., Subasinghe, C., Haldar, S., Croce, C. M., Yum, S., Cohen, J. (1990) Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res. 50, 6565-6570.
18. Ziegler, A., Luedke, G. H., Fabbro, D., Altmann, K. H., Stahel, R. A., Zangemeister-Wittke, U. (1997) Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the bcl-2 coding sequence. J. Natl. Cancer Inst. 89, 1027-1036.
19. Zangemeister-Wittke, U., Leech, S. H., Olie, R. A., Simoes-Wust, A. P., Gautschi, O., Luedke, G. H., Natt, F., Haner, R., Martin, P., Hall, J., Nalin, C. M., Stahel, R. A. (2000) A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin. Cancer Res. 6, 2547-2555.
20. Cotter, F. E., Johnson, P., Hall, P., Pocock, C., al Mahdi, N., Cowell, J. K., Morgan, G. (1994) Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 9, 3049-3055.
21. Waters, J. S., Webb, A., Cunningham, D., Clarke, P. A., Raynaud, F., di Stefano, F., Cotter, F. E. (2000) Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 18, 1812-1823.
22. Webb, A., Cunningham, D., Cotter, F., Clarke, P. A., di Stefano, F., Ross, P., Corbo, M., Dziewanowska, Z. (1997) BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349, 1137-1141.
23. Hartmann, G., Bidlingmaier, M., Eigler, A., Hacker, U., Endres, S. (1997) Cytokines and therapeutic oligonucleotides. Cytokines Cell. Mol. Ther. 3, 247-256.
24. Krieg, A. M., Wagner, H. (2000) Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. Immunol. Today 21, 521-526.
25. Monia, B. P, (1997) First- and second-generation antisense oligonucleotide inhibitors targeted against human c-raf kinase. Ciba Found. Symp. 209, 107-119.
26. Baker, B. F., Lot, S. S., Condon, T. P., Cheng-Flournoy, S., Lesnik, E. A., Sasmor, H. M., Bennett, C. F. (1997) 2′-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem. 272, 11994-12000.
27. Hartmann, G., Krug, A., Waller-Fontaine, K., Endres, S. (1996) Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin. Mol. Med. 2, 429-438.
28. Krieg, A. M., Yi, A. K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., Klinman, D. M. (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546-549.
29. Ballas, Z. K., Rasmussen, W. L., Krieg, A. M. (1996) Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 157, 1840-1845.
30. Hartmann, G., Weiner, G., Krieg, A. M. (1999) CpG DNA: a potent signal for growth, activation and maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA 96, 9305-9310.
31. Hartmann, G., Krieg, A. M. (1999) CpG DNA and LPS induce distinct patterns of activation in human monocytes. Gene Ther. 6, 893-903.
32. Hartmann, G., Weeratna, R. D., Ballas, Z. K., Payette, P., Blackwell, S., Suparto, I., Rasmussen, W. L., Waldschmidt, M., Sajuthi, D., Purcell, R. H., Davis, H. L., Krieg, A. M. (2000) Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164, 1617-1624.
33. Hartmann, G., Krieg, A. M. (2000) Mechanism and function of a newly identified CpG DNA motif in human primary cells. J. Immunol. 164, 944-952.
34. Karlin, S., Ladunga, I., Blaisdell, B. E. (1994) Heterogeneity of genomes: measures and values. Proc. Natl. Acad. Sci. USA 91, 12837-12841.
35. Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., Akira, S. (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-745.
36. Davis, H. L., Suparto, I. I., Weeratna, R. R., Jumintarto, Iskandriati, D. D., Chamzah, S. S., Ma'ruf, A. A., Nente, C. C., Pawitri, D. D., Krieg, A. M., Heriyanto, Smits, W., Sajuthi, D. D. (2000) CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 18, 1920-1924.
37. Jones, T. R., Obaldia 3rd, N., Gramzinski, R. A., Charoenvit, Y., Kolodny, N., Kitov, S., Davis, H. L., Krieg, A. M., Hoffman, S. L. (1999) Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine 17, 3065-3071.
38. Vabulas, R. M., Pircher, H., Lipford, G. B., Hacker, H., Wagner, H. (2000) CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses. J. Immunol. 164, 2372-2378.
39. Jahrsdörfer, B., Hartmann, G., Racila, E., Jackson, W., Muhlenhoff, L., Meinhardt, G., Endres, S., Link, B. K., Krieg, A. M., Weiner, G. J. (2001) CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J. Leukoc. Biol. 69, 81-88.
40. Decker, T., Schneller, F., Sparwasser, T., Tretter, T., Lipford, G. B., Wagner, H., Peschel, C. (2000) Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 95, 999-1006.
41. Decker, T., Schneller, F., Kronschnabl, M., Dechow, T., Lipford, G. B., Wagner, H., Peschel, C. (2000) Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. Exp. Hematol. 28, 558-568.
42. Yi, A. K., Hornbeck, P., Lafrenz, D. E., Krieg, A. M. (1996) CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J. Immunol. 157, 4918-4925.
43. Yi, A. K., Krieg, A. M. (1998) CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of I kappa B alpha and I kappa B beta and sustained activation of nuclear factor-kappa B/c-Rel. J. Immunol. 160, 1240-1245.
44. Macfarlane, D. E., Manzel, L., Krieg, A. M. (1997) Unmethylated CpG-containing oligodeoxynucleotides inhibit apoptosis in WEHI 231 B lymphocytes induced by several agents: evidence for blockade of apoptosis at a distal signalling step. Immunology 91, 586-593.
45. Klasa, R. J., Bally, M. B., Ng, R., Goldie, J. H., Gascoyne, R. D., Wong, F. M. (2000) Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin. Cancer Res. 6, 2492-2500.
46. Hartmann, G., Krug, A., Bidlingmaier, M., Hacker, U., Eigler, A., Albrecht, R., Strasburger, C. J., Endres, S. (1998) Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes. J. Pharmacol. Exp. Ther. 285, 920-928.
47. Pepper, C., Thomas, A., Hoy, T., Cotter, F., Bentley, P. (1999) Anti-sense-mediated suppression of bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 107, 611-615.
48. Cotter, F. E. (1997) Antisense therapy for lymphomas. Hematol. Oncol. 15, 3-11.
49. Cotter, F. E., Waters, J., Cunningham, D. (1999) Human bcl-2 antisense therapy for lymphomas. Biochim. Biophys. Acta 1489, 97-106.
50. Koty, P. P., Zhang, H., Levitt, M. L. (1999) Antisense bcl-2 treatment increases programmed cell death in non-small cell lung cancer cell lines. Lung Cancer 23, 115-127.
51. Jansen, B., Schlagbauer-Wadl, H., Brown, B. D., Bryan, R. N., van Elsas, A., Muller, M., Wolff, K., Eichler, H. G., Pehamberger, H. (1998) bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med. 4, 232-234.
52. Kitada, S., Takayama, S., De Riel, K., Tanaka, S., Reed, J. C. (1994) Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res. Dev. 4, 71-79.
53. Kitada, S., Miyashita, T., Tanaka, S., Reed, J. C. (1993) Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. Antisense Res. Dev. 3, 157-169.
54. Zangemeister-Wittke, U., Schenker, T., Luedke, G. H., Stahel, R. A. (1998) Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br. J. Cancer 78, 1035-1042.
55. Schlagbauer-Wadl, H., Klosner, G., Heere-Ress, E., Waltering, S., Moll, I., Wolff, K., Pehamberger, H., Jansen, B. (2000) bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. J. Investig. Dermatol. 114, 725-730.
56. Lopes de Menezes, D. E., Hudon, N., McIntosh, N., Mayer, L.D. (2000) Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin. Cancer Res. 6, 2891-2902.
57. Sun, S., Zhang, X., Tough, D. F., Sprent, J. (1998) Type I interferon-mediated stimulation of T cells by CpG DNA. J. Exp. Med. 188, 2335-2342.
58. Davis, T. A., Maloney, D. G., Grillo-Lopez, A. J., White, C. A., Williams, M. E., Weiner, G. J., Dowden, S., Levy, R. (2000) Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin. Cancer Res. 6, 2644-2652.
59. Steis, R. G., Foon, K. A., Longo, D. L. (1987) Current and future uses of recombinant interferon alpha in the treatment of low-grade non-Hodgkin's lymphoma. Cancer 59, 658-663.
60. Langenmayer, I., Nerl, C., Knauf, W., Dempster, S., Hallek, M., Adorf, D., Dietzfelbinger, H., Busch, R., Ziegler-Heitbrock, H. W., Thiel, E., Emmerich, B. (1996) Interferon-alpha 2b (IFN alpha) for early-phase chronic lymphocytic leukaemia with high risk for disease progression: results of a randomized multicentre study. Br. J. Haematol. 94, 362-369.
61. Ziegler-Heitbrock, H. W., Thiel, E. (1990) Recombinant IFN-alpha in lymphomas. J. Investig. Dermatol. 95, 213S-215S.
62. Kranzer, K., Bauer, M., Lipford, G. B., Heeg, K., Wagner, H., Lang, R. (2000) CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon-gamma production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12. Immunology 99, 170-178.
63. Weiner, G. J., Liu, H. M., Wooldridge, J. E., Dahle, C. E., Krieg, A. M. (1997) Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA 94, 10833-10837.
64. Wooldridge, J. E., Ballas, Z., Krieg, A. M., Weiner, G. J. (1997) Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 89, 2994-2998.
65. Carpentier, A. F., Chen, L., Maltonti, F., Delattre, J. Y. (1999) Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res. 59, 5429-5432.
66. Brunner, C., Seiderer, J., Schlamp, A., Bidlingmaier, M., Eigler, A., Haimerl, W., Lehr, H. A., Krieg, A. M., Hartmann, G., Endres, S. (2000) Enhanced dendritic cell maturation by tumor necrosis factor-a or CpG DNA drives T cell-activation in vitro and therapeutic anti-tumor immune responses in vivo. J. Immunol. 165, 6278-6286.
67. Smetsers, T. F., Boezeman, J. B., Mensink, E. J. (1996) Bias in nucleotide composition of antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 6, 63-67.